Certified by Founder
Lodge
IMU Biosciences
start up
United Kingdom
- London
- 25/01/2024
- Series A
- $14,639,787
Mapping the immune system in unprecedented detail and scale. IMU’s discovery platform is building a new understanding of the immune system across health and disease, through next generation high resolution, systems-level immune profiling with AI & ML analytics.
- Industry Biotechnology Research
- Website https://www.imubiosciences.com/
- LinkedIn https://www.linkedin.com/company/imubiosciences/